Roxwood Medical Proceeds With Full U.S. Launch Of Its Microcross Catheter After 500+ Patients Are Successfully Treated During Limited Release

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Roxwood Medical Inc. reported today that more than 500 patients have been successfully treated as part of the initial limited release of its MicroCross™ Catheter, the latest addition to Roxwood Medical’s expanding product line. The MicroCross Catheter is FDA-cleared and offered in two sizes (Micro14 and Micro18) for use in the coronary and peripheral vasculatures, providing enhanced guidewire support through challenging and tortuous anatomy.

“These are now our frontline tools to navigate across difficult lower extremity blockages, leading to effective treatment of our patients’ severe peripheral arterial disease (PAD).”

Compatible with Roxwood Medical’s CenterCross™ Catheter, MicroCross is comprised of an ultra-low profile shaft featuring variable pitch braid technology and a state-of-the-art lubricious coating. These features allow for enhanced trackability and guidewire support while navigating tortuous regions of the coronary and peripheral vasculature.

“I have been impressed with the performance of the catheter in my early experience,” stated Dr. Jeff Moses of Columbia University Medical Center (New York, N.Y.). “The increased complexity of our treatment approach for coronary occlusions puts a lot of demand on the tools we use. The low profile and trackability of Micro14 provides an exciting new tool for us to access and cross these highly complex lesions.”

“Since first using the Micro14 and Micro18, we continue to be struck by the performance of the catheters, which have quickly become an essential part of our Critical Limb Ischemia toolkit,” said Dr. Fadi Saab of Metro Heart Hospital (Wyoming, Mich.). “These are now our frontline tools to navigate across difficult lower extremity blockages, leading to effective treatment of our patients’ severe peripheral arterial disease (PAD).”

Roxwood Medical President & CEO, Mehrdad Farhangnia, added, “We’re thrilled with the positive feedback we have received from our clinicians during our limited release of Micro14 and Micro18. The full US launch of the MicroCross Catheter represents another important milestone for the company. The success we have seen to date is a reflection of our commitment to the growing Complex PCI movement. Beyond the MicroCross, CenterCross and MultiCross Catheters, we have a rich pipeline of new products we plan to bring to the US market in 2016.”

About Roxwood Medical, Inc.
Roxwood Medical (www.roxwoodmedical.com) is a privately held medical device company focused on empowering physicians through the design and development of innovative and cost-effective catheter platforms for cardiovascular disease. To date, Roxwood has been granted US FDA 510(k) clearance for the MultiCross, CenterCross, and MicroCross Catheter platforms.